An Inventive Report of Inducing Apoptosis in Non-Small Cell Lung Cancer (NSCLC) Cell Lines by Transfection of MiR-۴۳۰۱

Publish Year: 1399
نوع سند: مقاله کنفرانسی
زبان: English
View: 315

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

CIGS16_053

تاریخ نمایه سازی: 14 اردیبهشت 1400

Abstract:

Background and Aim: Based on recent studies, new therapeutic strategies have been developed for cancer treatment using microRNAs (miRNAs). With this view, miRNAs manipulating techniques can be considered as novel therapeutic prospects for cancer treatment. In this study, we evaluated the expression of miR-۴۳۰۱ in human lung cancer cell lines and investigated its potential role in cell proliferation and tumor suppression on non-small cell lung cancer (NSCLC) cells.Methods: We used quantitative real-time polymerase chain reaction (qRT-PCR) to examine the level of miR-۴۳۰۱ expression in human lung cancer cell lines (A۵۴۹, QU-DB) and non-malignant lung epithelial cells (HFLF-PI۵). Then, we investigated the effect of miR-۴۳۰۱ by transfecting it into these cell lines and probing for cancer cell viability and apoptosis using the MTT assay, flow cytometry and immunofluorescence staining.Results: Our results showed that the expression level of miR-۴۳۰۱ was significantly reduced in human lung cancer cell lines (P<۰.۰۰۱). When miR-۴۳۰۱ was transfected in lung cancer cells, their cell proliferation was suppressed and apoptosis induced. This decline in cell survival was confirmed by the MTT assay. Transfection of miR-۴۳۰۱ caused an increase in early and late apoptotic cells in all lung cancer cell lines tested.Conclusion: Our findings show that miR-۴۳۰۱ may act as a lung cancer suppressor through targeting of proteins involved in cell proliferation and survival. For this reason, targeting miR-۴۳۰۱ may provide a new strategy for the diagnosis and treatment of patients with this deadly disease. This article is protected by copyright. All rights reserved.

Authors

Abbas Jamshidiavval

Department of Biology, Faculty of Life Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran

Ahmad Majd

Department of Biology, Faculty of Life Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran

Naghmeh Gholipour

Department of Medical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran,Iran

Kambiz akbari noghabi

Department of environmental sciences, National Institute of Genetic Engineering and Biotechnology (NIGEB),Tehran, Iran

anna ohradanova-repic

Molecular Immunology Unit, Institute for Hygiene and Applied Immunology, Center for Pathophysiology,Infectiology and Immunology, Medical University of Vienna, Vienna, Austria

ghasem ahangari

Department of Medical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran,Iran